{"id":33,"date":"2026-07-14T18:10:15","date_gmt":"2026-07-14T18:10:15","guid":{"rendered":"https:\/\/blitzlab.eu\/blog-tesamorelin-kaufen\/"},"modified":"2026-10-23T23:36:58","modified_gmt":"2026-10-23T21:36:58","slug":"buy-tesamorelin","status":"publish","type":"page","link":"https:\/\/blitzlab.eu\/en\/blog-tesamorelin-kaufen\/","title":{"rendered":"Tesamorelin kaufen \u2013 Forschungsleitfaden"},"content":{"rendered":"
\n
Home<\/a>\u203a<\/span>Blog<\/a>\u203a<\/span>Buy Tesamorelin 2026<\/span><\/div>\n\n

Buy Tesamorelin 2026 \u2014 GHRH(1-44) analogue for GH\/IGF-1 axis research (EU)<\/h1>\n

Peptide Research \u00b7 28 June 2026 \u00b7 11 min read \u00b7 Research Use Only<\/p>\n\n

\n In short:<\/strong> Tesamorelin (TH9507) is a stabilised analogue of the GHRH(1-44) sequence<\/strong> from 44 amino acids with a trans-3-hexenoyl modification at the N-terminus. This research guide summarises, the published in-vitro and animal model literature<\/strong> documented for Tesamorelin \u2013 from GHRH receptor binding to models of the GH\/IGF-1 axis. At BlitzLab as 10mg vial<\/strong> with batch-related Certificate of Analysis (COA)<\/a>, HPLC \u2265 99 %, EU delivery. Price: <\/strong>. For research use only (RUO).\n <\/div>\n
<\/svg> Scientific-factual research guide. Summarises published study observations. No health, dosage or application advice, no statement about suitability in humans. Research Use Only.<\/div>\n\n

Tesamorelin at a glance<\/h2>\n \n
Designation<\/th>Tesamorelin (GHRH(1-44) analogue)<\/td><\/tr>\n
Identity<\/th>Stabilised GHRH analogue of 44 amino acids (trans-3-hexenoyl-modified)<\/td><\/tr>\n
Synonyms<\/th>GHRH analogue, TH9507, Egrifta<\/td><\/tr>\n
Research context<\/th>GHRH receptor binding, GH\/IGF-1 axis models (in vitro\/animal model)<\/td><\/tr>\n
CAS number<\/th>218949-48-5 (the batch-specific COA is authoritative)<\/span><\/td><\/tr>\n
Molecular formula<\/th>See CoA<\/td><\/tr>\n
Form<\/th>Lyophilised powder (freeze-dried), sealed vial<\/td><\/tr>\n
Amount<\/th>10 mg per vial<\/td><\/tr>\n
Purity<\/th>\u226599% (HPLC), identity confirmed by LC-MS<\/td><\/tr>\n
Analysis<\/th>External third-party laboratory, batch-specific COA<\/td><\/tr>\n
Intended use<\/th>For Research Use Only (RUO)<\/td><\/tr>\n
Price<\/th> \u00b7 Shipping from Germany<\/td><\/tr>\n <\/table>\n\n

What is Tesamorelin?<\/h2>\n

Tesamorelin \u2013 also known in the literature as TH9507<\/strong> managed \u2013 is a synthetic, stabilised analogue of human Growth Hormone-Releasing Hormone (GHRH). It is based on the complete GHRH(1-44) sequence, which is a chain of 44 amino acids, and carries at the N-terminus a trans-3-Hexenoyl modification<\/strong>. This modification is the structural feature that distinguishes tesamorelin from the native GHRH sequence and is described in research as a stabilising element. The peptide is supplied as a lyophilised product in a sealed vial (10 mg). In laboratory research, Tesamorelin serves as a defined reference substance for the investigation of GHRH-related model systems. The CAS number and molecular formula are documented in the batch-specific certificate of analysis; the COA of the delivered batch is always authoritative.<\/p>\n\n

Molecular profile & target structure<\/h2>\n

Tesamorelin is derived from GHRH(1-44), the natural sequence by which the hypothalamic releasing hormone binds to the GHRH receptor<\/strong> binds. The GHRH receptor is a G protein-coupled receptor that is characterised in the preclinical literature as a binding site for GHRH and its analogues. Through the N-terminal trans-3-hexenoyl group, tesamorelin is described in studies as an analogue stabilised compared to the native sequence. The combination of a defined 44-amino acid sequence, clearly characterisable modification, and good analytical accessibility makes tesamorelin a frequently used reference in study models concerning GHRH receptor binding and downstream GH-\/IGF-1 axis<\/strong>.<\/p>\n\n

What in-vitro and animal model studies document<\/h2>\n

The following summary reflects only what is described in the publicly accessible preclinical literature<\/strong> \u2013 it is not a statement about an effect or suitability in humans.<\/p>\n